Back to search

Peptide record

TPDB07272

PTP7 Antibacterial Anticancer Hemolysis Toxicity standard
13 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB07272
PTP7
Antibacterial Anticancer Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF HemoPI PD_Hemolysis
standard
No
A 13-aa standard natural multi-activity (Antibacterial, Anticancer, Hemolysis, and other sources) peptide sequence curated from AntiBP3, dbAMP, Peptipedia, and other sources, with an available 3D structural model.
Sequence
FLGALFKALSKLL
Physicochemical Analysis
C71H117N15O15
RNDCEQHIMPTWYV
L
1420.80
10.60
2
0
9
+2
-3.28
1.477
165.38
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
1
Residue Composition
number
2
A
0
R
0
N
0
D
0
C
0
E
0
Q
1
G
0
H
0
I
5
L
2
K
0
M
2
F
0
P
1
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 2 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 0 L: 5 K: 2 M: 0 F: 2 P: 0 S: 1 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
13
C71H117N15O15
1420.80
10.60
+2
-3.28
1.477
Free
L
Linear
Free
Antibacterial
Gaegurin
Evidence Records 14 records
Evidence 1 Activity

Activity

IC50
IC50=8.01 µg/ml
Anticancer
8.01 µg/mL

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2003

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50=6.71 µg/ml
Anticancer
6.71 µg/mL

Target

Renal Cancer
293
Renal

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2003
Evidence 3 Activity

Activity

IC50
IC50=5.01 µg/ml
Anticancer
5.01 µg/mL

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2003
Evidence 4 Activity

Activity

IC50
IC50=5.4 µg/ml
Anticancer
5.4 µg/mL

Target

Liver Cancer
Hep3B
Liver

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2003
Evidence 5 Activity

Activity

IC50
IC50=5.25 µg/ml
Anticancer
5.25 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2003
Evidence 6 Activity

Activity

% Hemolysis
Hemolysis
6 %
Human RBCs: less than 6% hemolysis at 100 µg/ml

Target

Human RBCs

Source & Reference

Hemolytik PD_Hemolysis
DRAMP4
Peptides. 2003 Jul 24(7):945-53.

Other

Source Activity Label Source Definition
Hemolysis
Hemolytik experimentally validated hemolytic peptide annotation.
Evidence 7 Activity

Activity

6% Hemolysis
Toxicity
100 µg/mL
Hemolytic Cytotoxic
6% Hemolysis | 100 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Correlation between the activities of alpha-helical antimicrobial peptides and hydrophobicities represented as RP HPLC retention times. | Peptides | 2005
Evidence 8 Activity

Activity

IC50
Toxicity
6.71±0.47 µg/mL
Cytotoxic
IC50 | 6.71±0.47 | µg/mL | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. | Peptides | 2003
Evidence 9 Activity

Activity

IC50
Toxicity
8 µM
Cytotoxic
IC50 | 8 | µM | target cell: Normal breast cells MCF-10a

Target

Normal breast cells MCF-10a

Source & Reference

NA
DBAASP
Correlation between the activities of alpha-helical antimicrobial peptides and hydrophobicities represented as RP HPLC retention times. | Peptides | 2005
Evidence 10 Activity

Activity

4.5% Hemolysis
Toxicity
7.5 µM
Hemolytic Cytotoxic
4.5% Hemolysis | 7.5 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Activity and selectivity of histidine-containing lytic peptides to antibiotic-resistant bacteria. | Arch Microbiol | 2012
Evidence 11 Activity

Activity

11% Hemolysis
Toxicity
15 µM
Hemolytic Cytotoxic
11% Hemolysis | 15 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Activity and selectivity of histidine-containing lytic peptides to antibiotic-resistant bacteria. | Arch Microbiol | 2012
Evidence 12 Activity

Activity

25% Hemolysis
Toxicity
30 µM
Hemolytic Cytotoxic
25% Hemolysis | 30 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Activity and selectivity of histidine-containing lytic peptides to antibiotic-resistant bacteria. | Arch Microbiol | 2012
Evidence 13 Activity

Activity

IC50
Toxicity
6.71
Hemolytic Cytotoxic
Hemolytic_activity: Human RBCs: less than 6% hemolysis at 100 µg/ml | Cytotoxicity: HEK293: IC50=6.71 ± 0.47 µg/ml MCF-10A: IC50=8 µM

Target

erythrocytes

Source & Reference

NA
DRAMP
Peptides. 2003 Jul 24(7):945-53.
Evidence 14 Hemolysis

Activity

6 %
% Hemolysis
Human RBCs: less than 6% hemolysis at 100 µg/ml
Hemolysis

Target

Human RBCs

Source & Reference

HemoPI PD_Hemolysis
Peptides. 2003 Jul 24(7):945-53.
DRAMP4
PD_Hemolysis